Journal article
Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis
Abstract
Background: Clinical trials have shown rofecoxib, a selective inhibitor of cyclo-oxygenase-2, to be associated with fewer gastrointestinal complications than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs).Objective: To evaluate the potential clinical and economic consequences of rofecoxib prescription in Ontario, Canada, for patients with osteoarthritis (OA) aged >65 years who did not respond to paracetamol (acetaminophen) …
Authors
Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
Journal
PharmacoEconomics, Vol. 19, No. 10, pp. 1039–1049
Publisher
Springer Nature
Publication Date
10 2001
DOI
10.2165/00019053-200119100-00005
ISSN
1170-7690
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDecision Support TechniquesGastrointestinal HemorrhageHumansIsoenzymesLactonesMembrane ProteinsOntarioOsteoarthritisProstaglandin-Endoperoxide SynthasesStomach UlcerSulfones